Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.

Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.

Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.

ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.

Lisa Carter-Bawa, PhD, APRN, discusses policy barriers, arts-based outreach, AI, and stigma in lung cancer screening.

Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.